IIT-H startup among top five at BioAsia summit

75 startups from five countries were in the race

February 22, 2020 12:05 am | Updated 12:05 am IST - Hyderabad

Heamac Healthcare team receiving the award during BioAsia 2020 in the city.

Heamac Healthcare team receiving the award during BioAsia 2020 in the city.

A startup incubated at Indian Institute of Technology-Hyderabad (IIT-H) has made it to the top-5 list from among 75 startups from India, Switzerland, Germany, Australia and the UK that took part in a competition held as part of BioAsia 2020 in Hyderabad.

The ‘Startup Stage’ contestants were short-listed from over 350 applications on the basis of the innovativeness of their products or solutions, development stage and market readiness.

The startup in question — Heamac Healthcare, incubated at the IIT-H’s Center for Healthcare Entrepreneurship (CfHE) — provides solution to neonatal jaundice management using an evolutionary phototherapy device called ‘nLite360’, which reduces by 70% the burden of the doctor struggling to treat every newborn with minimal resources available. It also reduces 35% of the total treatment time, say founders Prasad Muddam and Akitha Kolloju, who graduated from the unique one-year fellowship programme offered by the CfHE.

Kolloju credited the achievement to the biodesign fellowship program at CfHE, where she was trained to identify the need in this segment. Highlighting the role of CfHE in developing such a start-up, IIT-H director B.S. Murty said centre has been a cradle of biomedical innovations with special focus on creating social impact by addressing unmet medical needs of the rural population.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.